Sökning: WFRF:(Lehto P) > Delivery of Oligonu...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 06360naa a2200865 4500 | |
001 | oai:gup.ub.gu.se/310167 | |
003 | SwePub | |
008 | 240528s2021 | |||||||||||000 ||eng| | |
009 | oai:research.chalmers.se:4b22760b-ae02-469a-99ef-ccad1c110d76 | |
009 | oai:prod.swepub.kib.ki.se:147800841 | |
024 | 7 | a https://gup.ub.gu.se/publication/3101672 URI |
024 | 7 | a https://doi.org/10.1021/acsnano.1c050992 DOI |
024 | 7 | a https://research.chalmers.se/publication/5263122 URI |
024 | 7 | a http://kipublications.ki.se/Default.aspx?queryparsed=id:1478008412 URI |
040 | a (SwePub)gud (SwePub)cthd (SwePub)ki | |
041 | a eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a art2 swepub-publicationtype |
100 | 1 | a Bost, J. P.u Karolinska Institutet4 aut |
245 | 1 0 | a Delivery of Oligonucleotide Therapeutics: Chemical Modifications, Lipid Nanoparticles, and Extracellular Vesicles |
264 | c 2021-09-10 | |
264 | 1 | b American Chemical Society (ACS),c 2021 |
520 | a Oligonucleotides (ONs) comprise a rapidly growing class of therapeutics. In recent years, the list of FDA-approved ON therapies has rapidly expanded. ONs are small (15-30 bp) nucleotide-based therapeutics which are capable of targeting DNA and RNA as well as other biomolecules. ONs can be subdivided into several classes based on their chemical modifications and on the mechanisms of their target interactions. Historically, the largest hindrance to the widespread usage of ON therapeutics has been their inability to effectively internalize into cells and escape from endosomes to reach their molecular targets in the cytosol or nucleus. While cell uptake has been improved, "endosomal escape" remains a significant problem. There are a range of approaches to overcome this, and in this review, we focus on three: altering the chemical structure of the ONs, formulating synthetic, lipid-based nanoparticles to encapsulate the ONs, or biologically loading the ONs into extracellular vesicles. This review provides a background to the design and mode of action of existing FDA-approved ONs. It presents the most common ON classifications and chemical modifications from a fundamental scientific perspective and provides a roadmap of the cellular uptake pathways by which ONs are trafficked. Finally, this review delves into each of the above-mentioned approaches to ON delivery, highlighting the scientific principles behind each and covering recent advances. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Reumatologi och inflammation0 (SwePub)302102 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Rheumatology and Autoimmunity0 (SwePub)302102 hsv//eng |
650 | 7 | a NATURVETENSKAPx Biologix Cellbiologi0 (SwePub)106042 hsv//swe |
650 | 7 | a NATURAL SCIENCESx Biological Sciencesx Cell Biology0 (SwePub)106042 hsv//eng |
650 | 7 | a NATURVETENSKAPx Biologix Biokemi och molekylärbiologi0 (SwePub)106022 hsv//swe |
650 | 7 | a NATURAL SCIENCESx Biological Sciencesx Biochemistry and Molecular Biology0 (SwePub)106022 hsv//eng |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Medicinska och farmaceutiska grundvetenskaperx Cell- och molekylärbiologi0 (SwePub)301082 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Basic Medicinex Cell and Molecular Biology0 (SwePub)301082 hsv//eng |
653 | a oligonucleotide | |
653 | a oligonucleotide delivery | |
653 | a intracellular trafficking | |
653 | a endosomal escape | |
653 | a RNA therapeutics | |
653 | a lipid nanoparticles | |
653 | a extracellular | |
653 | a vesicles | |
653 | a cellular uptake | |
653 | a duchenne muscular-dystrophy | |
653 | a rnai-based nanomedicines | |
653 | a receptor-mediated | |
653 | a uptake | |
653 | a small organic-compounds | |
653 | a locked nucleic-acid | |
653 | a messenger-rna | |
653 | a in-vivo | |
653 | a cationic lipids | |
653 | a sirna delivery | |
653 | a antisense oligonucleotides | |
653 | a Chemistry | |
653 | a Science & Technology - Other Topics | |
653 | a Materials Science | |
653 | a intracellular trafficking | |
700 | 1 | a Barriga, H.u Karolinska Institutet4 aut |
700 | 1 | a Marco, Maugeri,d 1983u Karolinska Institutet,Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för reumatologi och inflammationsforskning,Institute of Medicine, Department of Rheumatology and Inflammation Research4 aut0 (Swepub:gu)xmauma |
700 | 1 | a Gallud, Audrey,d 1988u AstraZeneca AB,Chalmers tekniska högskola,Chalmers University of Technology4 aut0 (Swepub:cth)gallud |
700 | 1 | a Marco, Maugeri,d 1983u Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för reumatologi och inflammationsforskning,Institute of Medicine, Department of Rheumatology and Inflammation Research,Imperial College of Science, Technology and Medicine,Karolinska Institutet4 aut0 (Swepub:gu)xmauma |
700 | 1 | a Gupta, D.u Karolinska Institutet4 aut |
700 | 1 | a Lehto, T.u Karolinska Institutet4 aut |
700 | 1 | a Valadi, Hadi,d 1963u Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för reumatologi och inflammationsforskning,Institute of Medicine, Department of Rheumatology and Inflammation Research,University of Gothenburg4 aut0 (Swepub:gu)xvalha |
700 | 1 | a Esbjorner, E. K.4 aut |
700 | 1 | a Stevens, M. M.4 aut |
700 | 1 | a El-Andaloussi, S.u Karolinska Institutet4 aut |
700 | 1 | a Esbjörner Winters, Elin,d 1978u Chalmers tekniska högskola,Chalmers University of Technology4 aut0 (Swepub:cth)eline |
710 | 2 | a Karolinska Institutetb Institutionen för medicin, avdelningen för reumatologi och inflammationsforskning4 org |
773 | 0 | t Acs Nanod : American Chemical Society (ACS)g 15:9, s. 13993-14021q 15:9<13993-14021x 1936-0851x 1936-086X |
856 | 4 | u https://pubs.acs.org/doi/pdf/10.1021/acsnano.1c05099 |
856 | 4 | u https://research.chalmers.se/publication/526312/file/526312_Fulltext.pdfx primaryx freey FULLTEXT |
856 | 4 8 | u https://gup.ub.gu.se/publication/310167 |
856 | 4 8 | u https://doi.org/10.1021/acsnano.1c05099 |
856 | 4 8 | u https://research.chalmers.se/publication/526312 |
856 | 4 8 | u http://kipublications.ki.se/Default.aspx?queryparsed=id:147800841 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.